• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

Verily Teams up with Mayo Clinic to Develop Clinical Support Tool

Share:

August 30, 2021

Alphabet’s life science subsidiary Verily is teaming up with the Mayo Clinic on a new effort to develop a digital point-of-care clinical decision support tool. The partnership will start by zeroing in on cardiometabolic conditions and is directed at contextualizing information and giving care guidelines to clinicians.

In the partnership, the Mayo Clinic will be responsible for the clinical content from its multidiscipline and multispecialty practices. Verily will take on the tech side, providing its clinical analytics to deliver insights to healthcare professionals.

The goal is for clinicians to tap into a number of data resources from Mayo Clinic-approved sources and de-identified health record data. The pair plan to first launch the tool at the Mayo Clinic, but it could expand to other hospitals.

WHY IT MATTERS

The collaboration is pitched as a way to help clinicians quickly tap into guidelines and information in order to boost patient care.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

According to an AMA survey, an increasing number of doctors are using clinical decision support tools. In 2019, 37% of clinicians reported currently using a clinical decision support tool, up from 28% in 2016.

“The exponential growth in medical discovery and knowledge has reached the point where it is almost impossible for caregivers to keep up with the latest advances. This tool will make Mayo Clinic’s deep expertise available to care teams so that they can have concise, relevant, and applicable answers to clinical questions, tailored to the specific needs of each patient,” said Bradley Leibovich, M.D., medical director of Mayo Clinic’s Center for Digital Health. “We hope it can be used as a GPS for patient care.”

THE LARGER TREND

In December, Verily landed $700 million in funding to expand its business. Since then, the company has been busy. Last week it acquired clinical trial management system SignalPath in order to help build out its clinical trial platform Baseline, which works in the decentralized clinical trial and hybrid trial space.

In early August, the company announced a partnership with dental care company Colgate-Palmolive in an effort to find the link between oral health and overall health.

Earlier this week news broke that Verily’s sister company Google is dismantling its health division, instead of dispersing its Google Health team to other departments. So far there has been no mention of Verily in the news and whether or not it would be positioned to absorb any of these efforts.

Source: Mobihealthnews

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Medtronic Expands AI-Driven Partnership with Cosmo Pharmaceuticals to Transform EndoscopyMedtronic Expands AI-Driven Partnership with Cosmo Pharmaceuticals to Transform Endoscopy
  • Why AI-Driven Cancer Screening Will Soon Become Standard of CareWhy AI-Driven Cancer Screening Will Soon Become Standard of Care
  • TrialCard Announces Acquisition Of Mango HealthTrialCard Announces Acquisition Of Mango Health
  • Logibec Expands Into Virtual Care with Ontario-Based AcquisitionLogibec Expands Into Virtual Care with Ontario-Based Acquisition
  • 7 Homo species close to present human that existed on the Earth.7 Homo species close to present human that existed on the Earth.
  • Merck Acquires Imago and its LSD1 Inhibitors in $1.3B DealMerck Acquires Imago and its LSD1 Inhibitors in $1.3B Deal
  • Q BioMed Announces Legal Settlement And Acquisition Of FDA Approved Non-Opioid Metastatic Cancer Pain DrugQ BioMed Announces Legal Settlement And Acquisition Of FDA Approved Non-Opioid Metastatic Cancer Pain Drug
  • Inovalon Launches FHIR-Based Solution for Health Plan ComplianceInovalon Launches FHIR-Based Solution for Health Plan Compliance

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications